Workflow
湖北华强科技股份有限公司 关于签署日常经营性合同的自愿性披露公告

Core Viewpoint - The company has signed a supply agreement for a new product, the cartridge bottle rubber sealing component, which is expected to positively impact its operating performance if executed successfully [1][4]. Group 1: Agreement Details - The company has entered into a supply agreement with a domestic pharmaceutical company, with an estimated order value of approximately 20 million RMB [2][3]. - The agreement is classified as a routine operational contract and does not require approval from the board of directors or shareholders [2]. - The agreement is set to be executed from the date of signing until December 31, 2025 [5]. Group 2: Product and Market Impact - The new product represents a breakthrough in key technologies through independent research and innovation, achieving commercial batch supply for the first time [1][4]. - The product's development demonstrates the company's research and development capabilities and aligns with international standards, enhancing its competitiveness in the pharmaceutical packaging market [1][4]. Group 3: Risk Analysis - The agreement includes clear stipulations regarding the amount, payment schedule, rights and obligations of both parties, and breach of contract responsibilities [6]. - Despite both parties having the capacity to fulfill the agreement, external factors such as macroeconomic changes, policy shifts, and unforeseen circumstances may affect execution [6].